
Biofrontera (BFRI) Stock Forecast & Price Target
Biofrontera (BFRI) Analyst Ratings
Bulls say
Biofrontera Inc. is positioned for potential revenue acceleration with new indications for the treatment of superficial Basal Cell Carcinoma and Actinic Keratoses expected to reach the market in 2026 and 2027. The company is also likely to benefit from an increase in sales personnel and favorable reimbursement conditions, which enhance Ameluz's competitive position against cryotherapy and could drive customer conversions to photodynamic therapy. Furthermore, historical sales trends indicate that the fourth quarter will be crucial for revenue growth, especially with the new labeling that permits a higher dosage of Ameluz, increasing the potential for sales in this key period.
Bears say
Biofrontera Inc. is facing a significant challenge as its revenue of $8.6 million fell short of both the $10.6 million estimate and the consensus, indicating potential difficulties in meeting financial expectations. Furthermore, the revised stock outlook suggests a decrease in valuation, with expectations of trading at approximately 3x 2026 revenue, down from a prior target of $7 per share to $2.75 per share. Additionally, the risk of regulatory surprises looms, which could adversely affect revenue streams and lead to increased operating costs, further complicating the company's financial landscape.
This aggregate rating is based on analysts' research of Biofrontera and is not a guaranteed prediction by Public.com or investment advice.
Biofrontera (BFRI) Analyst Forecast & Price Prediction
Start investing in Biofrontera (BFRI)
Order type
Buy in
Order amount
Est. shares
0 shares